氨溴特罗口服液治疗小儿支气管肺炎的临床效果

Clinical effect of ambroxol oral solution in the treatment of children with bronchial pneumonia

目的分析氨溴特罗口服液治疗小儿支气管肺炎的临床效果。方法随机抽取100例本院2016年10月至2017年11月收治的支气管肺炎患儿,根据随机信封法将其分为对照组(50例)与试验组(50例)。给予对照组患儿常规治疗,给予试验组患儿常规治疗+氨溴特罗口服液治疗。分析两组患儿的治疗效果。结果治疗后,试验组患儿的临床症状评分低于对照组与治疗前,住院时间短于对照组(P<0.05)。试验组患儿的TNF-α、IL-8及IgE水平均低于对照组(P<0.05)。两组不良反应总发生率比较,差异不显著(P>0.05)。结论在支气管肺炎患儿临床治疗中,应用氨溴特罗口服液治疗既可改善临床症状及炎症反应,又可缩短住院时间,治疗效果显著,值得临床推广应用。

Objective To analyze the clinical effect of ambroxol oral solution in children with bronchial pneumonia.Methods A total of 100 children with bronchial pneumonia admitted in our hospital from October 2016 to November 2017 were randomly selected, according to the random envelope method, they were divided into control group（50 cases） and experimental group（50 cases）. The control group was given routine treatment, the experimental group was given routine treatment＋ambroxol oral solution treatment. The treatment effects of the two groups were analyzed. Results After treatment,the clinical symptom score in the experimental group was lower than those in the control group and before treatment, and the hospital stay was shorter than that of the control group（P〈0.05）. The levels of TNF-α, IL-8 and IgE in the experimental group were lower than those in the control group（P〈0.05）. There was no significant difference in the total incidences of adverse reactions in the two groups（P〉0.05）. Conclusion In the clinical treatment of children with bronchial pneumonia, the ambroxol oral solution treatment can not only improve clinical symptoms and immune function, but also shorten the hospital stay, with a significant treatment effect. It is worthy of clinical promotion and application.